Remifentanil-Induced Symmetric Drug-Related Intertriginous and Flexural Exanthema: A Diagnosis Challenge in an Intensive Care Patient

Martins JF¹, Alen Coutinho I²*, Castro M³, Carvalho J², Faria C¹, Sousa E¹, Martins P¹.5

¹Intensive Medicine Departement, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
²Allergy and Clinical Immunology Departement, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
³Anesthesiology Departement, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
⁴Pathological Anatomy Departement, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
⁵Faculty of Medicine, University of Coimbra, Coimbra, Portugal
*Both authors contributed equally to this work

Corresponding author
Iolanda Alen Coutinho, MD
Serviço de Imunoalergologia, Centro Hospitalar e Universitário de Coimbra, Praceta Prof. Mota Pinto, 3000-075 Coimbra
E-mail: iolandaalen@gmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0764
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare sharply demarcated symmetric erythema of the gluteal and/or inguinal areas, and at least one other flexural localization, resulting from exposure to a systemic drug. The delay after exposure to the drug is usually short, occurring in days, and is independent of previous sensitization [1,2,3]. The pathophysiology of SDRIFE is complex and not fully understood; however, a T cell-mediated delayed hypersensitivity reaction and the excretion of certain drug metabolites from the eccrine glands on the affected areas appear to play a role [2,3]. Most cases are associated with antibiotics, particularly beta-lactams, especially aminopenicillins and cephalosporins, but other drugs are reported, such as carbapenems, antifungal, antihypertensives, radio-contrast media, chemotherapeutic agents, and monoclonal antibodies [2,4].

The diagnosis is based on five criteria: exposure to a systemically administered drug either at the first or repeated dose (excluding contact allergens), sharply demarcated erythema of the gluteal/perianal area and/or V-shaped erythema of the inguinal/perigenital area, involvement of at least one other intertriginous/flexural localization, symmetry of affected areas, and absence of systemic symptoms and signs [5,6]. Positive skin tests or in vitro tests support the diagnosis, although they are usually inconclusive [5].

The treatment involves discontinuation of the suspected drug, symptomatic control of pruritus, and administration of topical corticosteroids [5].
A 29-year-old, previously healthy, non-atopic male patient was admitted to the emergency department (ED) after trauma due to a motorcycle collision. On the admission to the ED, the patient was hemodynamically unstable with a shock index of 1.89, corresponding to a high risk of mortality. Focused assessment with sonography of the trauma (FAST sonography) showed hemoperitoneum, and emergency exploratory laparotomy confirmed traumatic splenic rupture, resulting in splenectomy. He was admitted to the Intensive Care Unit (ICU) and analgosedated with remifentanil and propofol. On D3 of ICU admission, the patient was diagnosed with early-onset ventilator-associated pneumonia, and started ceftriaxone. In order to optimize analgosedation and improve patient-ventilator interaction, midazolam was started. After 48 hours, he developed extensive demarcated erythema with a symmetrical presentation limited to the gluteal, perianal, inguinal and flexural areas. Over the next 24 hours, the erythema evolved into vesicles and blisters presented at the flexures, some with loss of epidermal integrity. It was not possible to assess the pruritus due to the patient’s sedation status. Laboratory evaluation with complete blood count, liver, and renal function were unremarkable. Allergy and Clinical Immunology was consulted and considered the diagnostic hypothesis of SDRIFE, which was corroborated by punch skin biopsy findings: superficial perivascular eosinophils and rare neutrophils infiltrates, associated with intra-epidermal blisters containing lymphocytes and rare neutrophils. Ceftriaxone was discontinued on D6 of the ICU stay, as it was consider the main suspected agent, given the prevalence reported in the literature. Antibiotic therapy was switched to ciprofloxacin, based on bronchoalveolar aspirate and antibiotic sensitivity test that identified Neisseria meningitidis. Topical corticosteroid (0.5 mg/g clobetasol propionate, ointment) was applied in the accessible areas. Considering the patient’s state of immobilization in the polytrauma clinical context, the degree of extension and severity of skin lesions, some with loss of skin integrity, the patient's septic status, and the need to control new possible sources of infection, it was decided to associate systemic corticosteroid therapy (prednisolone 0.5 mg/kg/day, endovenous) for three days, resulting in clinical resolution. Improved hemodynamic and respiratory status allowed weaning from analgosedation with suspension of midazolam on D6, remifentanil and propofol on D7 of the ICU stay.

Eight weeks later, the Allergy diagnostic workup was carried out based on the drug chronology (Figure 1). Latex allergy was excluded. Skin prick test (SPT) and
intradermal tests (IDT) with immediate and delayed readings were performed for main suspected drugs with concentrations according to EAACI/ENDA recommendations: ceftriaxone (SPT 2mg/mL; IDT 2mg/mL), midazolam (SPT 5mg/mL; IDT 0.5mg/mL), remifentanil (SPT 0.05mg/mL; IDT 0.005mg/mL), and propofol, (SPT 10mg/mL; IDT 1mg/mL), all with negative results. Patch tests were performed in accordance with the European Society of Cutaneous Allergy and Contact Dermatitis (ESCD) recommendations (ceftriaxone, midazolam, remifentanil, and propofol at 10% and 30% petrolatum concentrations), and routinely included European baseline series evaluation, with readings on D3, D4 and D7. Patch test results were positive for remifentanil at 10% and 30% on D3. Lymphocyte transformation tests (LTT) were performed 12 weeks after clinical resolution. Recommended concentrations for LTT with 3 fivefold dilutions of each drug were used, and LTT result was considered positive if the stimulation index (SI) was higher than 2 for two different concentrations [7]. The result was positive for remifentanil, with a SI of 2.1 and 2.3 for 100mcg/mL and 200mcg/mL concentrations, respectively, and were negative for the remaining drugs tested. Drug provocation test (DPT) was negative for ceftriaxone (cumulative dose of 1000mg). Drug provocation tests were not performed for the remaining suspected drugs, due to potent pharmacological effects of these drug groups, namely respiratory depression and sedation.

SDRIFE is a rare condition, with few data in the literature. In our case report, the allergological diagnostic investigation was carried out based on a detailed analysis of the complex drug chronology. Considering literature data, such as Häusermann et al [6], in which antibiotics, mainly the beta-lactam group, were the main aetiologial agents in cases of SDRIFE, ceftriaxone was initially considered the main suspected agent in our case report. Based on skin and in vitro tests results, and negative drug provocation test, this hypothesis was excluded. Although the LTT is a safe in vitro test, only a few authors have performed the LTT for the diagnosis of SDRIFE cases [8,9,10]. For the remaining suspected drugs, patch and LTT tests were crucial to guide the identification of the culprit drug, revealing positive results to indicate remifentanil.

Given that our patient had all the diagnostic criteria for SDRIFE, the histopathological findings, and the positivity of patch and in vitro tests for remifentanil, the diagnosis of remifentanil-induced SDRIFE was established, avoiding the DPT and re-exposure.
risks. Additionally, these positive results support the involvement of a type IV hypersensitivity mechanism in SDRIFE.

Depending on the clinical context, the diagnosis of a delayed drug reaction can be more or less challenging, especially in ICU, polymedicated and sedated patients. A detailed review of all exposures is essential to guide the search for the etiological agent.

The complex drug chronology, the presence of drugs most frequently implicated in this type of hypersensitivity reaction, such as the beta-lactam group, and the patient's sedation state, made allergic investigation a diagnostic challenge in this case.

To the best of our knowledge this is the first case described of remifentanil-induced SDRIFE.

**Conflict of interest**
The authors have no conflicts of interest.

**Funding**
This study did not receive any funding.
References

1. De Risi-Pugliese T, Barailler H, Hamelin A, Amsler E, Gaouar H, Kurihara F, Jullie ML, et al. Symmetrical drug-related intertriginous and flexural exanthema: A little-known drug allergy. J Allergy Clin Immunol Pract. 2020;8(9):3185-3189.e4.

2. Nespoulous L, Matei I, Charissoux A, Bédane C, Assikar S. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis. 2018;1–3.

3. Can C, Yazicioglu M, Ozdemir PG, Kilavuz S, Tastekin E. Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. Allergol Immunopathol (Madr). 2014 Mar-Apr;42(2):173-5. doi: 10.1016/j.aller.2012.10.005.

4. Blanco Garcia-Granero D, Barranco R, García-Moguel I, Velasco V, Diéguez Pastor MC. First Case of Symmetric Drug-Related Intertriginous and Flexural Exanthema Induced by Meropenem. J Investig Allergol Clin Immunol. 2021 Mar 3:0. doi: 10.18176/jiaci.0685. Epub ahead of print. PMID: 33661103.

5. Tan, Sze-Chin; Tan, Justina W.-L. Symmetrical drug-related intertriginous and flexural exanthema, Current Opinion in Allergy and Clinical Immunology: August 2011 - Volume 11 - Issue 4 - p 313-318 doi: 10.1097/ACI.0b013e3283489d5f

6. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004 Nov-Dec;51(5-6):297-310. doi: 10.1111/j.0105-1873.2004.00445.x.

7. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-44. doi: 10.1111/j.1398-9995.2007.01553.x.

8. Obara K, Maejima H, Katayama C, Takasu H, Amoh Y. A case of symmetrical drug-related intertriginous and flexural exanthema induced by acetaminophen. J Dermatol. 2014;41(12):1132-3. doi: 10.1111/1346-8138.12666.

9. Tan, S.-C., Tan, J. W.-L. Symmetrical drug-related intertriginous and flexural exanthema. Current Opinion in Allergy and Clinical Immunology.2011.11(4), 313–8. doi:10.1097/aci.0b013e3283489d5.

10. Daito J, Hanada K, Katoh N, KatohS, Sakamoto K, Asai J, et al. Symmetrical Drug-Related Intertriginous and Flexural Exanthema Caused by Valacyclovir. Dermatology. 2009.218(1), 60–2. doi:10.1159/000167829.
Figure 1. Drug chronology administered during ICU stay.

| Drug                     | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 | D9 | D10 | D11 | D12 | D13 | D14 | D15 | D16 |
|--------------------------|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|
| Propofol                 |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Midazolam                |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Dexmedetomidine          |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Remifentanil             |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Paracetamol              |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Tramadol                 |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Haloperidol              |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Noradrenaline            |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Furosemide               |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Tranexamic acid          |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Ceftriaxone              |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Ciprofloxacin            |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Enoxaparin               |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Pantoprazole             |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Metoclopramide           |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Corticotherapy           |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |
| Hospitalization days    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |

**Legend:**
- **Main suspected drug**
- **Drug administered**
- **Drug not administered**
- **Topical corticosteroid (0.5 mg/g clobetasol propionate, ointment) and systemic corticosteroid therapy (prednisolone 0.5 mg/kg/day) administered**

**ICU – Intensive Care Unit**